<DOC>
	<DOCNO>NCT03009396</DOCNO>
	<brief_summary>An open label extension RHB-104-01 Study .</brief_summary>
	<brief_title>Open Label Efficacy Safety Anti-MAP ( Mycobacterium Avium Ssp . Paratuberculosis ) Therapy Adult Crohn 's Disease</brief_title>
	<detailed_description>An Open Label Phase III Study Assess Efficacy Safety Fixed-Dose Combination RHB-104 Subjects Active Crohn 's Disease Despite 26 Weeks Participation MAP US RHB-104-01 Study .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
	<mesh_term>Paratuberculosis</mesh_term>
	<criteria>Signed fully inform consent provide per protocol . Participation RHB10401 26 week , Crohn 's Disease Activity Index ( CDAI ) score ≥ 150 Visit Week 26 . OR More 26 week , CDAI ≥150 Visit Week 26 subsequent visit , subject Week 26 52 within 4 week ( 28 day ) site activation ( e.g . Subject CDAI = 249 week 26 week 38 time site 's activation RHB10404 4week window enrol open label study via Optional Screening Visit ) Current treatment least one follow therapy may discontinue investigator clinically indicate 8 week open label RHB104 treatment : Oral 5acetyl salicylic acid ( 5ASA ) compound Azathioprine 6mercaptopurine ( 6MP ) methotrexate Infliximab adalimumab OR Current treatment corticosteroid therapy must begin taper 4 week treatment open label RHB104 ( Refer Appendix 13 ) White blood cell count ≥ 3.5x109 screening ( RHB10401 Visit Week 26 visit Optional Screening visit ) Subject agree use follow effective contraceptive method diaphragm , cervical cap , contraceptive sponge condom ) spermicidal foam/gel/cream/suppository IUD ( intrauterine device ) /IUS ( intrauterine system ) progestogen injection ( DepoProvera® ) throughout study least 6 week last study drug administration , unless subject partner subject postmenopausal otherwise incapable become pregnant reason surgery tubal ligation , vasectomy . Postmenopausal define experience 12 consecutive month without menstruation . In region local regulatory contraceptive requirement differ , ICF ( Informed Consent Form ) reflect local policy . 1 . Positive stool result C. difficile . 2 . Currently diagnosed history uveitis confirm either ophthalmologist optometrist . 3 . Treatment medication cause QT prolongation Torsades de Pointes , include limited : amiodarone , amitriptyline , astemizole , cisapride , citalopram dose great 20 mg/day , dihydroergotamine , disopyramide , dofetilide , dronedarone , ergotamine , ibutilide , ondansetron 5HT3 ( 5hydroxytryptamine ) receptor antagonist , pimozide , procainamide , quinidine , quinine , quinolones , ranolazine , risperidone , sotalol , terfenadine tolterodine . QT prolong drug may reference CredibleMeds® web site : http : //crediblemeds.org/index.php/drugsearch/ 4 . Treatment follow CYP3A4 interactive medication : alfentanyl , alprazolam , amlodipine , antiretroviral agent , apixaban , aprepitant , aripiprazole , atorvastatin , boceprevir , buspirone , carbamazepine , carvedilol , colchicine , cyclosporine , digoxin , diltiazem , estrogens , felodipine , fluconazole , fluvoxamine , grapefruit juice , haloperidol , ketoconazole , lovastatin , lurasidone , metoprolol , nefazodone , nifedipine , nisoldipine , nitrendipine , propranol , roflumilast , simvastatin , St. John 's wort , voriconazole . 5 . Any evidence newly diagnose significant hematological , hepatic , renal , cardiac , pulmonary , metabolic , neurological , psychiatric disease ( e.g . porphyria ) might interfere subject 's ability safely enter complete study requirement . 6 . Females positive pregnancy test lactating . 7 . Refusal sign study inform consent form . 8 . Inability able adequately communicate investigator respective designee and/or comply requirement entire study . 9 . Clinically significant abnormality hematology biochemistry confirm repeat test base investigator 's discretion , include limited , elevation great 2 time upper limit normal Aspartate Aminotransferase ( AST ) , Alanine Aminotransferase ( ALT ) , Alkaline Phosphatase ( ALP ) creatinine clearance less 60 ml/min screen via estimate CockcroftGault formula : Creatinine Clearance = [ 140 age year ] * weight ( kg ) / 72 * Serum Creatinine ( mg/dl ) [ multiply estimate rate 0.85 woman ] , use actual body weight . 10 . QTcF ( shorten QT interval heart rate ) &gt; 450ms male QTcF &gt; 460ms female , bundle branch block , major ST T wave abnormality make assessment QT impossible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Crohn 's Disease ,</keyword>
	<keyword>moderate severe</keyword>
	<keyword>remission</keyword>
	<keyword>Mycobacterium avium paratuberculosis</keyword>
	<keyword>antibiotic</keyword>
</DOC>